Monte Rosa Therapeutics, Inc. Common Stock (GLUE) Stock Price
GLUEStock
$13.38+177.02%52W
Market Cap$1.14B
P/E—
PEG Ratio—
Div yield—
Beta1.31
GLUE Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-42.28%
Price vs S&P 500 (4W)-14.55%
VGM Score29.52
GLUE Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.37 | -$0.43 | -17.58%(-$0.06) | |
| Q1 2026 | -$0.38 | -$0.45 | -19.07%(-$0.07) | |
| Q4 2025 | -$0.34 | -$0.55 | -63.38%(-$0.21) | |
| Q3 2025 | -$0.35 | -$0.33 | +6.38%(+$0.02) | |
| Q2 2025 | -$0.36 | -$0.15 | +58.80%(+$0.21) |
GLUE Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.27
4.27
4.27
4.27
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GLUEMonte Rosa Therapeutics, Inc. Common Stock | D | F | C | $13.38 |
| AMGNAmgen Inc | C | C | B | $432.42 |
| GILDGilead Sciences Inc | C | B | B | $145.68 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1023.21 |
| MRNAModerna, Inc. Common Stock | D | C | A | $137.99 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $207.88 |
| BIIBBiogen Inc. Common Stock | C | D | B | $218.50 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $102.08 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $154.06 |
| EXELExelixis Inc | C | B | B | $54.45 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $105.35 |
About Monte Rosa Therapeutics, Inc. Common Stock
Monte Rosa Therapeutics develops molecular glue degraders (MGDs), a novel class of small molecules designed to selectively degrade disease-relevant proteins by harnessing the body's natural protein destruction mechanisms. Leveraging its proprietary QuEEN platform and AI-driven discovery, the company has assembled a library of over 50,000 MGD candidates. Its lead program, MRT-2359, targets GSPT1 in MYC-driven tumors.